Johnson & Johnson Gets FDA Priority Review of Nipocalimab

Johnson & Johnson announces pause of all U.S. Varipulse cases
Johnson & Johnson announced that on January 5, “out of an abundance of caution,” Johnson & Johnson MedTech temporarily paused the U.S.
Dividend Roundup: Why I Prefer Johnson & Johnson Over Pfizer
Johnson & Johnson offers safer payouts and stronger growth. Discover why JNJ stock is the better dividend option compared to ...
Johnson & Johnson Pauses US Varipulse Procedures Amid Safety Review, Investigates Brain-Related Events
Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA therapy and 3D mapping for AFib treatment.
Cautious Outlook on Johnson & Johnson Amid Currency and Legal Challenges
Wells Fargo analyst Larry Biegelsen maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target ...
STAT2d
Johnson & Johnson says its lung cancer drug significantly extended survival
Johnson & Johnson says its bispecific antibody, paired with a Janssen drug, could change treatment for non-small lung cancer ...
Johnson & Johnson: A Potential Beneficiary Of A Great Rotation
JNJ has an attractive 3.41% dividend yield comparable to the yield on long-term bonds. Given the lack of price movement and ...
Hold Recommendation for Johnson & Johnson Amid Promising Drug Trials and Regulatory Challenges
Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) and keeping the price ...